Egetis Therapeutics AB (publ) (LON:0ABW)

Egetis Therapeutics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-319.3	-326.9	-193.8	-104.5	-178.02	-61.42
Depreciation & Amortization	0.9	3.6	2.7	2.5	0.4	0.21
Stock-Based Compensation	8	8	8.8	1.2	0.56	-
Other Operating Activities	9.9	6	-2.1	-1.1	0.38	-1.15
Change in Accounts Receivable	-0.9	-22.9	-10.7	3.1	16.43	0.05
Change in Other Net Operating Assets	85.4	53.8	21.6	-31.3	25.62	-0.33
Operating Cash Flow	-216	-278.4	-173.5	-130.1	-134.64	-62.64
Capital Expenditures	-	-	-	-0.2	-0.02	-
Cash Acquisitions	-	-	-1.7	-5	-59.52	-
Investment in Securities	0.4	-	-	-0.8	-	-
Other Investing Activities	0.1	-	-	-	0	-
Investing Cash Flow	0.5	-	-1.7	-6	-59.54	-
Long-Term Debt Issued	-	108.8	-	-	-	-
Long-Term Debt Repaid	-	-5.6	-9.1	-8.9	-0.22	-0.22
Net Debt Issued (Repaid)	103.2	103.2	-9.1	-8.9	-0.22	-0.22
Issuance of Common Stock	171.9	381.9	177.4	-	250.75	91.26
Other Financing Activities	-12.1	-26.2	-12.6	-	-22.13	-4.32
Financing Cash Flow	263	458.9	155.7	-8.9	228.41	86.72
Foreign Exchange Rate Adjustments	-2.4	-4.8	3.2	1.1	-1.47	1.15
Miscellaneous Cash Flow Adjustments	-0.2	-0.1	-	-	-	-
Net Cash Flow	44.9	175.6	-16.3	-143.9	32.75	25.23
Free Cash Flow	-216	-278.4	-173.5	-130.3	-134.66	-62.64
Free Cash Flow Margin	-318.11%	-483.33%	-767.70%	-341.10%	-331.18%	-75.87%
Free Cash Flow Per Share	-0.74	-1.07	-0.89	-0.72	-2.00	-1.21
Cash Interest Paid	4.1	4.1	0.1	-	0	0
Cash Income Tax Paid	0.1	0.1	-	-	-	-
Levered Free Cash Flow	-110.99	-165.35	-112.39	-90.55	-62.98	-41.71
Unlevered Free Cash Flow	-95.93	-162.79	-112.33	-90.43	-62.98	-41.7
Change in Net Working Capital	-78.1	-25.8	0.7	28.18	-46.75	0.28

Source: S&P Capital IQ. Standard template. Financial Sources.